Ironwood Pharmaceuticals, Inc is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea.

Sofar SpA manufactures pharmaceutical products, dietary supplements, and medical devices. The firm��s product areas include gastrointestinal, gynecology, dermatology, sleep disorders, pediatric, energy and movement, immune system, beauty and wellness, pregnancy area, weight control, urology, and OTC medications. The company was founded in 1968 and is headquartered in Trezzano Rosa, Italy.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

POZEN, Inc. manufactures and markets pharmaceutical products. Its Pipeline products are PA Product Portfolio, which is focused on integrated aspirin therapies that enable the full power of aspirin by reducing its potential gastrointestinal damage. The firm PA Product Portfolio consists of PA8140 and PA32540. The company was founded by John R. Plachetka in 1996 and is headquartered in Raleigh, NC.

Inspire Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The advanced compounds in the clinical pipeline are denufosol tetrasodium for cystic fibrosis and Prolacria for dry eye, both of which are in Phase III development, and AzaSite for blepharitis, which is in Phase II development.

Taisho Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following divisions: Self-Medication, Prescription Pharmaceutical and Overseas Development. The Self-Medication division deals with the research, development, and production of over-the-counter (OTC) drugs, medical supplies, food for specific health use, and hygiene products. The Prescription Pharmaceutical division handles research and development of new drugs in the fields of central nervous system diseases, metabolic diseases, infectious diseases, and inflammatory diseases. The Overseas Development division markets energy drinks and OTC pharmaceuticals overseas. The company was founded on October 12, 1912 and is headquartered in Tokyo, Japan.

KoBioLabs, Inc. engages in the research and development of the microbiome. Its product is involved in the industries such as therapeutics, diagnostics, cosmetics, agriculture, and veterinary medicine. The company was founded by Ko Gwang-Pyo on August 11, 2014 and is headquartered in Seoul, South Korea.

Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based on key insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

ReShape Lifesciences is America's premier weight-loss solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. T

Metabogen is an operator of a research and development company intended to offer biomarker and personalized treatment services. The company's services include integrating metagenomic data analysis with subsequent development and clinical programs as well as specializes in the identification and improvisation of indication-related bacterial strains, enabling probiotic industry to develop novel diagnostic tests and treatments.

Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.

Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA.

There is a large unmet medical need for patients suffering from functional Gastro-intestinal disorders. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic drug in the class of 5-HT4 agonists has shown to be effective for a range of these disorders.

NHC Communications, Inc. manufactures network switching and test equipment for local telecom service providers, corporations and multi-tenant buildings. It also offers the XPoint product line geared for smaller network applications. The company was founded in 1986 and is headquartered in Mount-Royal, Canada

Ancile Pharmaceuticals, Inc. is a private company headquartered in San Diego, CA. The firm develops and manufactures pharmaceuticals.

Synformulas is a probiotic company that develops medical devices, dietary supplements, and products for the balanced diet.

Dr. Falk Pharma GmbH engages in the development and sale of medication for indications in hematology and gastroenterology in Germany and internationally. The company principally offers prescription drugs that are used in treating inflammatory bowel diseases, cholestatic liver diseases, irritable bowel syndromes, and constipation, as well as for colon cleansing prior to colonoscopies. It also organizes and sponsors medical education events; and offers publications for healthcare professionals, as well as for patients and their families. The company was formerly known as Dr. Falk Arzneimittel GmbH & Co KG and changed its name to Dr. Falk Pharma GmbH in 1989. Dr. Falk Pharma GmbH was founded in 1960 and is headquartered in Freiburg, Germany